Trachoma is the world's leading infectious cause of blindness, and a single oral dose of azithromycin has become the cornerstone of treating and preventing it. This article lays out what trachoma actually is, why azithromycin works against it, the specific trials that established that fact, how the drug is dosed differently from the familiar five-day "Z-Pack," and what a patient or a community can realistically expect after treatment.

What Trachoma Is, and Why It Still Blinds People

Trachoma is caused by Chlamydia trachomatis, a bacterium spread through eye and nose discharge — on fingers, shared cloths, and the eye-seeking flies common where water is scarce and sanitation is poor. It is overwhelmingly a disease of poverty, concentrated in parts of sub-Saharan Africa, and pockets of the Middle East, Asia, and Latin America. Children carry the heaviest burden of active infection, often without knowing it.

The damage is cumulative. Repeated childhood infections produce chronic follicular conjunctivitis — redness, mild discharge, a gritty irritation that many families simply treat as ordinary "pink eye." Clinicians grade this progression using a simple World Health Organization scale: follicular inflammation (TF), intense inflammation (TI), scarring (TS), inturned eyelashes from that scarring (trichiasis, TT), and finally corneal clouding (CO) — the stage at which sight is lost. It is the scarring, not the acute infection itself, that eventually blinds a person, often decades after the childhood infections that caused it. This is a sobering reminder that a disease dismissed as minor in a five-year-old can steal an eighty-year-old's sight — a good argument for treating every case seriously, not just the ones that look severe today.

How Azithromycin Fights the Infection

Azithromycin is a macrolide antibiotic, chemically an "azalide" derivative of erythromycin — itself originally isolated from a soil bacterium, Streptomyces erythreus, discovered in the Philippines in the 1940s. It is a reasonable point of quiet wonder that a microorganism living in ordinary soil produced a molecule later refined into one of the most consequential public health tools of the last thirty years. Azithromycin blocks bacterial protein synthesis by binding the 50S ribosomal subunit, halting C. trachomatis replication. Its particular virtue for trachoma is pharmacokinetic rather than exotic biology: azithromycin concentrates in tissue, including ocular and lymphatic tissue, and persists there for days after a single dose, achieving with one tablet what older drugs needed weeks of repeated dosing to accomplish.

The Evidence: From Village Trials to Global Policy

Before the 1990s, trachoma was treated with tetracycline eye ointment applied twice daily for six weeks — a regimen that sounds modest on paper and performed poorly in practice, because sustaining twice-daily treatment across an entire village for six weeks proved close to impossible. The evidence that changed practice came from a series of community-based randomized trials.

A landmark trial conducted in The Gambia in the early 1990s, published in The Lancet, compared oral azithromycin against topical tetracycline and found the single oral dose at least as effective at clearing infection, with dramatically better adherence since it required no sustained cooperation from families. Follow-on community trials in Tanzania, led by researchers at Johns Hopkins University's Dana Center for Preventive Ophthalmology, and further work in Egypt, confirmed that mass treatment with oral azithromycin reduced both individual infection and community-level prevalence of active trachoma. A study published in JAMA in the late 1990s by Schachter and colleagues, examining community azithromycin distribution, reported substantial reductions in active disease prevalence following treatment rounds.

These findings were consistent enough that the Cochrane Collaboration's systematic review of trachoma treatment trials concluded oral azithromycin performs at least as well as topical tetracycline for clearing infection, with the practical advantage of far higher completion rates — a point that matters enormously in mass drug administration, where success depends on getting a whole community actually to take the medicine, not just having an effective molecule on paper. This body of evidence — multiple randomized community trials across different countries, replicated over more than a decade — is why the World Health Organization built its global trachoma elimination strategy, known by the acronym SAFE, around azithromycin as the "A."

It is worth being precise about the strength of this evidence: these are not small pilot studies or laboratory findings. They are cluster-randomized field trials involving thousands of participants, repeated across geographically and culturally distinct settings, with consistent results. That is about as strong as evidence gets in infectious disease control, and it is why azithromycin-based mass treatment has been adopted, not merely proposed, across dozens of endemic countries.

Dosing in Practice: Single Dose vs the "Z-Pack"

Here a common point of confusion deserves direct correction. The familiar "Z-Pack," prescribed in the United States for sinus infections, bronchitis, or strep throat, is a five-day tapered course — typically 500 mg on day one followed by 250 mg daily for four more days. That is not the regimen used for trachoma. Trachoma treatment relies on a single, one-time oral dose:

Tablets are commonly supplied in 250 mg or 500 mg strengths, so a 1 g adult dose may be taken as four 250 mg tablets or two 500 mg tablets at once, rather than spread across days. In mass drug administration campaigns, this single dose is repeated annually — typically for three to five consecutive years — in districts where surveys show active trachoma is common, because reinfection is expected between rounds until environmental and hygiene conditions improve. This is an important distinction from ordinary antibiotic courses: the single high dose is deliberate, not a shortcut, and taking a standard multi-day Z-Pack instead of the trachoma-specific single dose is not an equivalent substitution without a clinician's guidance.

One more point of accuracy: in the United States, trachoma is now exceedingly rare, largely eliminated through improved sanitation over the twentieth century, with only isolated historical cases in some remote communities. Azithromycin's use for trachoma is not a routine FDA-labeled indication for domestic prescribing in the way it is labeled for respiratory or skin infections; its use against trachoma is guided instead by World Health Organization protocols and international treatment programs. A patient or clinician anywhere in the world considering azithromycin for suspected trachoma should do so under direct medical supervision, with the diagnosis confirmed by someone trained to grade the disease properly.

What to Expect After Treatment

For an individual with active infection, azithromycin clears ocular C. trachomatis efficiently. Trial data generally show clearance rates in the range of roughly 80 to 95 percent when infection is assessed a few weeks after a single dose, though exact figures vary by study population and testing method. Clinically visible improvement — reduced redness, discharge, and follicular swelling — often begins within days, with substantial resolution over one to two weeks. Full resolution of visible inflammation can take somewhat longer in more advanced (TI-grade) cases.

What azithromycin cannot do is reverse scarring that has already formed. If repeated infections have already produced trichiasis — eyelashes turning inward against the cornea — that requires eyelid surgery, not antibiotics; this is the "S" in the WHO's SAFE framework, standing separately from the "A" for antibiotics. Families and clinicians should understand this distinction clearly: antibiotics treat active infection and interrupt transmission, but they are prevention and early treatment tools, not a repair for structural damage already done.

At the community level, expect gradual rather than immediate change. A single round of mass treatment typically reduces the prevalence of active disease substantially, but because reinfection cycles through households and villages via flies, shared water, and close contact, sustained reduction requires repeated annual rounds alongside the other SAFE components — facial cleanliness and environmental improvement, particularly access to clean water and proper waste disposal. Programs that pair azithromycin distribution with these measures have shown the most durable prevalence reductions in national trachoma surveys conducted over the past two decades.

Beyond the Pill: Why Antibiotics Alone Are Not the Whole Answer

It is tempting, given how effective and simple a single dose is, to think of azithromycin as a complete solution. The trial evidence itself argues against that. Communities that received antibiotics without corresponding improvements in water access and hygiene education saw infection return. Trachoma is, at its root, a disease of circumstance — crowding, dust, flies, and scarce water — and medicine works best there as one part of a broader responsibility that families, communities, and governments share for the conditions in which children live. This is consistent with a view of health care as genuine stewardship: a course of antibiotics matters, and so does the harder, longer work of clean water and clean faces, because both protect a child's sight for the rest of a long life. Patients and parents living in or traveling to endemic regions should discuss both dimensions — the medicine and the hygiene measures — with a physician familiar with local disease patterns, rather than treating a prescription as the end of the conversation.

Key takeaway: Azithromycin, given as a single oral dose rather than a multi-day course, is a well-evidenced and highly effective treatment for active trachoma infection, but lasting protection against blindness depends equally on hygiene, clean water, and — where scarring has already occurred — surgery, not on antibiotics alone.